Cargando…

Isoform-specific inhibition of FGFR signaling achieved by a de-novo-designed mini-protein

Cellular signaling by fibroblast growth factor receptors (FGFRs) is a highly regulated process mediated by specific interactions between distinct subsets of fibroblast growth factor (FGF) ligands and two FGFR isoforms generated by alternative splicing: an epithelial b- and mesenchymal c-isoforms. He...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Joon Sung, Choi, Jungyuen, Cao, Longxing, Mohanty, Jyotidarsini, Suzuki, Yoshihisa, Park, Andy, Baker, David, Schlessinger, Joseph, Lee, Sangwon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636537/ https://www.ncbi.nlm.nih.gov/pubmed/36288716 http://dx.doi.org/10.1016/j.celrep.2022.111545

Ejemplares similares

Heparin is essential for optimal cell signaling by FGF21 and for regulation of βKlotho cellular stability
por: An, Seong J., et al.
Publicado: (2023)

Cryo-EM analyses of KIT and oncogenic mutants reveal structural oncogenic plasticity and a target for therapeutic intervention
por: Krimmer, Stefan G., et al.
Publicado: (2023)

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Correction: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Structures and disulfide cross‐linking of de novo designed therapeutic mini‐proteins
por: Silva, Daniel‐Adriano, et al.
Publicado: (2018)

De novo design of luciferases using deep learning
por: Yeh, Andy Hsien-Wei, et al.
Publicado: (2023)

FGFR3-TACC3 fusion in solid tumors: mini review
por: Costa, Ricardo, et al.
Publicado: (2016)

De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
por: Cao, Longxing, et al.
Publicado: (2020)

Multiple mini-interviews as a predictor of academic achievements during the first 2 years of medical school
por: Lee, Hee Jae, et al.
Publicado: (2016)

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
por: Hyung, Sujin, et al.
Publicado: (2022)

FGF signalling through Fgfr2 isoform IIIb regulates adrenal cortex development
por: Guasti, Leonardo, et al.
Publicado: (2013)

Role of PKCε in the epithelial-mesenchymal transition induced by FGFR2 isoform switch
por: Ranieri, Danilo, et al.
Publicado: (2020)

Decoding the Conformational Selective Mechanism of FGFR Isoforms: A Comparative Molecular Dynamics Simulation
por: Zhang, Mingyang, et al.
Publicado: (2023)

Targeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models
por: Wu, Qing, et al.
Publicado: (2016)

De Novo Heterozygous Mutation in FGFR2 Causing Type II Pfeiffer Syndrome
por: Mosalli, Rafat, et al.
Publicado: (2022)

FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
por: Raja, Aroosha, et al.
Publicado: (2019)

A Cardiac Mitochondrial FGFR1 Mediates the Antithetical Effects of FGF2 Isoforms on Permeability Transition
por: Srisakuldee, Wattamon, et al.
Publicado: (2021)

Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma
por: Sengal, Asmerom T, et al.
Publicado: (2022)

Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity
por: Quambusch, Lena, et al.
Publicado: (2019)

Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression
por: Chen, G, et al.
Publicado: (2010)

The aberrant expression in epithelial cells of the mesenchymal isoform of FGFR2 controls the negative crosstalk between EMT and autophagy
por: Ranieri, Danilo, et al.
Publicado: (2021)

The impact of chemo- and radiotherapy treatments on selfish de novo FGFR2 mutations in sperm of cancer survivors
por: Maher, Geoffrey J, et al.
Publicado: (2019)

A de novo missense mutation of FGFR2 causes facial dysplasia syndrome in Holstein cattle
por: Agerholm, Jørgen S., et al.
Publicado: (2017)

Mini-open PLIF for Moderate to High Grade Spondylolisthesis: Technique to Achieve Spontaneous Reduction
por: Jeong, Se Ho, et al.
Publicado: (2015)

FGFR1 expression defines clinically distinct subtypes in pancreatic cancer
por: Haq, Farhan, et al.
Publicado: (2018)

Growth charts in FGFR2- and FGFR3-related faciocraniosynostoses
por: Ea, Caroline, et al.
Publicado: (2022)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

De novo transcriptome assembly of the Chinese pearl barley, adlay, by full-length isoform and short-read RNA sequencing
por: Kang, Sang-Ho, et al.
Publicado: (2018)

Current progress achieved in novel materials for supercapacitor electrodes: mini review
por: Najib, Sumaiyah, et al.
Publicado: (2019)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

Antibody-Mediated Targeting of the FGFR1c Isoform Increases Glucose Uptake in White and Brown Adipose Tissue in Male Mice
por: Lewis, Jo E., et al.
Publicado: (2017)

IDP-denovo: de novo transcriptome assembly and isoform annotation by hybrid sequencing
por: Fu, Shuhua, et al.
Publicado: (2018)

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
por: Meric-Bernstam, Funda, et al.
Publicado: (2022)

ASP5878, a selective FGFR inhibitor, to treat FGFR3‐dependent urothelial cancer with or without chemoresistance
por: Kikuchi, Aya, et al.
Publicado: (2017)

The First Case of B-lymphoblastic Leukemia Associated With t(7;8)(q34;p11.2) and FGFR1 Rearrangement
por: Cho, Ha-eun, et al.
Publicado: (2022)

The Coming of Age of De Novo Protein Design
por: David, Baker
Publicado: (2021)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion
por: Kim, Sun Young, et al.
Publicado: (2017)

Achieving high signal-to-noise in cell regulatory systems: Spatial organization of multiprotein transmembrane assemblies of FGFR and MET receptors
por: Blaszczyk, Michal, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pse92tfimgbm3h9j0huip37tc0